Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: A perspective review

Therapeutic Advances in Hematology

Volumn 4, Issue 2, 2013, Pages 93-102

  Adams, Rebecca L C ^a   Bird, Robert J ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

aplastic anaemia; deferasirox; efficacy; iron chelation; myelodysplastic syndrome; safety

Indexed keywords

AZACITIDINE; CREATININE; CYCLOSPORIN; DEFERASIROX; DEFEROXAMINE; FERRITIN; IRON; LENALIDOMIDE;

ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; ANAPHYLAXIS; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TRANSFUSION; CHELATION THERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR DISEASE; ERYTHEMA MULTIFORME; EYE DISEASE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL IRRITATION; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON BALANCE; IRON CHELATION; IRON OVERLOAD; KIDNEY DYSFUNCTION; LIPID PEROXIDATION; LIVER DISEASE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; MEDICATION COMPLIANCE; MOUTH ULCER; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PATIENT COMPLIANCE; PEPTIC ULCER; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RELAPSE; RETICULOENDOTHELIAL SYSTEM; SIDE EFFECT; STOMACH HEMORRHAGE; THALASSEMIA; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

EID: 84993729308     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712472355     Document Type: Review

References (61)

1. Aferrix Ltd (2012) Innovative Technologies for Diagnosis and Management of Iron Overload. Tel Aviv: Aferrix Ltd. [http://aferrix.com/%3E; viewed 16 September 2012]
2. Armand P. Kim H. Cutler C. Ho V. Koreth J. Alyea E. et al. (2007) Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109: 4586–4588.
3. Barosi G. Arbustini E. Gavazzi A. Grasso M. Pucci A. (1989) Myocardial iron grading by endomyocardial biopsy. A clinico-pathologic study on iron overloaded patients. Eur J Haematol 42: 382–388.
4. Bennett J. (2008) Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 83: 858–861.
5. Bird R. Kenealy M. Forsyth C. Wellwood J. Leahy M. Seymour J. et al. (2012) When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload? Intern Med J 42: 450–455.
6. Breccia M. Finsinger P. Loglisci G. Federico V. Santopietro M. Colafigli G. et al. (2012) Deferasirox treatment for myelodysplastic syndromes: ‘real-life’ efficacy and safety in a single-institution patient population. Ann Hematol 91: 1345–1349.
7. Buckstein R. Alibhai S. Lam A. Mamedov A. Zhang L. Lee C. et al. (2011) The health-related quality of life of MDS patients is impaired and most predicted by transfusion dependence, hemoglobin and age. Leuk Res 35: S55–S56.
8. Buckstein R. Alibhai S. Lam A. Zhang L. Mamedov A. Cheung M. et al. (2009) Transfusion dependence and low hemoglobin have the greatest impact on quality of life (QOL) in MDS patients – a tertiary care cross sectional and longitudinal study. Blood 114:2500.
9. Callens C. Coulon S. Naudin J. Radford-Weiss I. Boissel N. Raffoux E. et al. (2010) Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med 207: 731–750.
10. Cappellini M. Cohen A. Piga A. Bejaoui M. Perrotta S. Leyta A. et al. (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with B-thalassemia. Blood 107: 3456–3462.
11. Chan G. Chan S. Ho P. Ha S. (2009) Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pheumoniae and Aeromonas hydrophilia isolated from transfusion-dependent thalassemia patients. Hemoglobin 33: 353–360.
12. Galanello R. Piga A. Cappellini M. Forni G. Zappu A. Origa R. et al. (2008) Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol 48: 428–435.
13. Gattermann N. Finelli C. Porta M. Fenaux P. Ganser A. Guerci-Bresler A. et al. (2010) Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 34: 1143–1150.
14. Gattermann N. Finelli C. Porta M. Fenaux P. Stadler M. Guerci-Bresler A. et al. (2012 a) Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica 97: 1364–1371.
15. Gattermann N. Greenberg P. Urabe A. Habr D. Kpamegan E. Porter J. (2011) Transfused Myelodysplastic syndromes (MDS) patients have severe iron overload and relevant improvements in iron burden and liver function with deferasirox treatment: results from a pooled analysis. Blood 118:5019.
16. Gattermann N. Jarisch A. Schlag R. Blumenstengel K. Goebeler M. Groschek M. et al. (2012 b) Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies e Xtend and eXjange. Eur J Haematol 88: 260–268.
17. Giagounidis A. Al-Ali H. Mohr A. Haase D. Hofmann W. Kreuzer K. et al. (2012) Iron chelaton therapy with deferasirox: optimizing dosage and therapy initiation. Tumordiagnostik und Therapie 33: 29–33.
18. Giardina P. Goldberg S. Parkhurst Cain J. Chirnomas D. Esposito J. Paley C. et al. (2011) ‘The palatability and tolerability of deferasirox (Exjade®) taken with meals, different liquids, or crushed and added to food. Paper presented to 24th Annual American Society of Pediatric Hematology Oncology Meeting, Baltimore, MD, USA, 13–16 April 2011.
19. Greenberg P. Attar E. Bennett J. Bloomfield C. de Castro C. Deeg H. et al. (2011) Myelodysplastic syndromes. J Natl Compr Canc Netw 9: 30–56.
20. Greenberg P. Koller C. Cabantchik Z. Warsi G. Glynos T. Paley C. et al. (2010) Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 34: 1560–1565.
21. Guariglia R. Martorelli M. Villani O. Pietrantuono G. Mansueto G. D'Auria F. et al. (2011) Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res 35: 566–570.
22. Hershko C. (2010) Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci 1202: 1–9.
23. Hershko C. Graham G. Bates G. Rachmilewitz E. (1978) Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 40: 255–263.
24. Ibrahim A. Gebermariam T. Fu Y. Lin L. Husseiny M. French S. et al. (2007) The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 117: 2649–2657.
25. Ibrahim A. Spellberg B. Edwards J. Jr (2008) Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 21: 620–625.
26. Kikuchi S. Kobune M. Iyama S. Sato T. Murase K. Kawano Y. et al. (2012) Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radic Biol Med 53: 643–648.
27. Kontoghiorghes G. Kolnagou A. Skiada A. Petrikkos G. (2010) The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies. Hemoglobin 34: 227–239.
28. Lee J. Jang P. Chung N. Cho B. Jeong D. Kim H. (2011) Iron chelation therapy with deferasirox results in recovery of hematopoiesis in a child with aplastic anemia. Pediatr Hematol Oncol 28: 718–720.
29. Lee J. Yoon S. Shen Z. Ganser A. Hsu H. Habr D. et al. (2010) Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 116: 2448–2454.
30. Leitch H. (2011), Optimizing therapy for iron overload in the myelodysplastic syndromes recent developments. Drugs 71: 155–177.
31. List A. Baer M. Steensma D. Raza A. Esposito J. Martinez-Lopez N. et al. (2009) Two-year analysis of efficacy and safety of deferasirox (Exjade (registered trademark)) treatment in myelodysplastic syndrome patients enrolled in the US 03 study. Blood 114:3829.
32. List A. Baer M. Steensma D. Raza A. Esposito J. Martinez-Lopez N. et al. (2012) Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 30: 2134–2139.
33. Ma Y. Zhou T. Kong X. Hider R. (2012) Chelating agents for the treatment of systemic iron overload. Curr Med Chem Cardiovasc Hematol Agents 19: 2816–2827.
34. Mahesh S. Ginzburg Y. Verma A. (2008), Iron overload in myelodysplastic syndromes. Leuk Lymphoma 49: 427–438.
35. Mahindra A. Bolwell B. Sobecks R. Rybicki L. Pohlman B. Dean R. et al. (2009) Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation. Br J Haematol 146: 310–316.
36. Majhail N. Lazarus H. Burns L. (2010) A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors. Biol Blood Marrow Transplant 16: 832–837.
37. Malcovati L. (2007) Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 31: S2–S6.
38. Messa E. Carturan S. Maffe C. Pautasso M. Bracco E. Roetto A. et al. (2010) Deferasirox is a powerful NF-kappa B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica 95: 1308–1316.
39. Messa E. Cilloni D. Messa F. Arruga F. Roetto A. Saglio G. (2008) Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 120: 70–74.
40. Neukirchen J. Fox F. Kundgen A. Nachtkamp K. Strupp C. Haas R. et al. (2012) Improved survival in MDS patients receiving iron chelation therapy – a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk Res 36: 1067–1070.
41. Nishiuchi T. Okutani Y. Fujita T. Yoshida K. Ohnishi H. Haba R. (2010) Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome. Int J Hematol 91: 333–335.
42. Nolte F. Angelucci E. Beris P. Macwhannell A. Selleslag D. Schumann C. et al. (2011) Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Leuk Res 35: 1131–1135.
43. Novartis Pharmaceuticals Australia Pty Ltd (2012) Exjade TGA Approved Product Information. North Ryde, NSW: Novartis Pharmaceuticals Australia Pty Ltd. [viewed 27 August 2012]
44. Novartis Pharmaceuticals Corporation (2012) Exjade (Deferasirox). East Hanover, NJ: Novartis Pharmaceuticals Corporation. [http://www.us.exjade.com/index.jsp?usertrack.filter_applied=true&NovaId=2935376911799956419%3E; viewed 16 September 2012]
45. Olivieri N. Brittenham G. Matsui D. Berkovitch M. Blendis L. Cameron R. et al. (1995) Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med 332: 918–922.
46. Ponticelli C. Musallam K. Cianciulli P. Cappellini M. (2010) Renal complications in transfusion-dependent beta thalassaemia. Blood Rev 24: 239–244.
47. Porter J. Bowden D. Economou M. Troncy J. Ganser A. Habr D. et al. (2012) Health-related quality of life, treatment satisfaction, adherence and persistence in beta-thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the EPIC clinical trial. Anemia 2012: 297641.[epub]
48. Porter J. Galanello R. Saglio G. Neufeld E. Vichinsky E. Cappellini M. et al. (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 80: 168–176.
49. Pullarkat V. (2009) Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 114: 5251–5255.
50. Pullarkat V. (2010) Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv Hematol 2010.
51. Pullarkat V. Blanchard S. Tegtmeier B. Dagis A. Patane K. Ito J. et al. (2008) Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 42: 799–805.
52. Robins-Browne R. Prpic J. (1983) Desferrioxamine and systemic yersiniosis. Lancet 2: 1372.
53. Rose C. Brechignac S. Vassilief D. Pascal L. Stamatoullas A. Guerci A. et al. (2010) Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myelodysplasies). Leuk Res 34: 864–870.
54. Sechaud R. Dutreix C. Balez S. Pommier F. Dumortier T. Morisson S. et al. (2008) Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Int J Clin Pharmacol Ther 46: 102–108.
55. Sivgin S. Eser B. Bahcebasi S. Kaynar L. Kurnaz F. Uzer E. et al. (2012) Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hemopoietic stem cell transplantation (alloHSCT). Ann Hematol 91: 743–749.
56. Spellberg B. Ibrahim A. Chin-Hong P. Kontoyiannis D. Morris M. Perfect J. et al. (2012) The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 67: 715–722.
57. Taher A. Cappellini M. Vichinsky E. Galanello R. Piga A. Lawniczek T. et al. (2009) Efficacy and safety of deferasirox doses of > 30 mg / kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 147: 752–759.
58. Tunc B. Karakurt N. Yarali N. Azik F. Kara A. Ulha V. et al. (2012) Deferasirox therapy in children with Fanconi aplastic anemia. J Pediatr Hematol Oncol 34: 247–251.
59. Vichinsky E. (2008), Clinical application of deferasirox: practical patient management. Am J Hematol 83: 398–402.
60. Virtanen J. Remes K. Itala-Remes M. Saunavaara J. Komu M. Partanen A. et al. (2012) The relationship between cardiac and liver iron evaluated by MR imaging in haematological malignancies and chronic liver disease. Blood Cancer J 2: e49.
61. Zurlo M. de Stefano P. Borgna-Pignatti C. Di Palma A. Piga A. Melevendi C. et al. (1989) Survival and causes of death in thalassaemia major. Lancet 2: 27–30.